A large number of human clinical trials have been conducted since 2017.
Aiming for great improvement
Clinical trials with huge potential
At present, we have an on-going trial targeting Alzheimer´s Disease. It is a huge on-going effort involving more than 600 patients in a double blind, placebo trial involving nine major hospitals in Turkey. The trial is based on six months of treatment with the aim to improve cognitive function (memory loss).
the trial started in September 2025
This is what you need to know:
- Nine hospitals in five different cities in Turkey
- Primary Endpoint: Change in Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) score from baseline (start of trial) to end-of-treatment (6 months)
- Dose and formulation: Two daily doses of CMA2, sachets, 20 g
- Minimum 676 completed patient and 26 weeks of treatment
- Data handled and analysed by Swedish-based CRO (Veranex).
- Quality assurance by Swedish firm (Aurevia)